Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial

Prospective evidence regarding the combination of programmed cell death (PD)−1 and angiogenesis inhibitors in treating locally advanced gastric cancer (LAGC) is limited. In this multicenter, randomized, phase 2 trial (NCT04195828), patients with gastric adenocarcinoma (clinical T2-4N + M0) were rand...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature communications 2024-01, Vol.15 (1), p.41-41, Article 41
Hauptverfasser:	Lin, Jian-Xian, Tang, Yi-Hui, Zheng, Hua-Long, Ye, Kai, Cai, Jian-Chun, Cai, Li-Sheng, Lin, Wei, Xie, Jian-Wei, Wang, Jia-Bin, Lu, Jun, Chen, Qi-Yue, Cao, Long-Long, Zheng, Chao-Hui, Li, Ping, Huang, Chang-Ming
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4028/546 692/4028/67/1059/2325 692/4028/67/1504/1829 82/51 Adenocarcinoma Angiogenesis inhibitors Apoptosis Cancer Cell death Chemotherapy Gastric cancer Humanities and Social Sciences multidisciplinary Paclitaxel Patients PD-1 protein Science Science (multidisciplinary) Survival Tumor cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Prospective evidence regarding the combination of programmed cell death (PD)−1 and angiogenesis inhibitors in treating locally advanced gastric cancer (LAGC) is limited. In this multicenter, randomized, phase 2 trial (NCT04195828), patients with gastric adenocarcinoma (clinical T2-4N + M0) were randomly assigned (1:1) to receive neoadjuvant camrelizumab and apatinib combined with nab-paclitaxel plus S-1 (CA-SAP) or chemotherapy SAP alone (SAP) for 3 cycles. The primary endpoint was the major pathological response (MPR), defined as
ISSN:	2041-1723 2041-1723
DOI:	10.1038/s41467-023-44309-5